Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cumulative incidences of new geriatric syndromes.

References

  1. Giralt SA. Hematopoietic cell transplantation for older adults. In: Korc-Grodzicki B, Tew WP, editors. Handbooks of geriatrics oncology—practical guide to caring for the older cancer patient. New York, NY: Demos Medical Publishing; 2017:241–54.

  2. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–9.

    Article  Google Scholar 

  3. Hashmi SK, Bredeson C, Duarte RF, Farnia S, Ferrey S, Fitzhugh C, et al. National Institutes of Health blood and marrow transplant late effects initiative: the healthcare delivery working group report. Biol Blood Marrow Transplant. 2017;23:717–25.

    Article  Google Scholar 

  4. Rosko A, Artz A. Aging: treating the older patient. Biol Blood Marrow Transplant. 2017;23:193–200.

    Article  Google Scholar 

  5. Lin RJ, Hilden PD, Elko TA, Dahi PD, Shahrokni A, Jakubowski AA, et al. Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults. Blood Adv. 2019;3:12–20.

    Article  CAS  Google Scholar 

  6. Sorror ML, Storb RF, Sandmaier BM, Maziart RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249–56.

    Article  Google Scholar 

  7. Jonkman NH, Colpo M, Klenk J, Todd C, Hoekstra T, Del Panta V, et al. Development of a clinical prediction model for the onset of functional decline in people aged 65–75 years: pooled analysis of four European cohort studies. BMC Geriatr. 2019;19:179.

    Article  Google Scholar 

  8. Arora M, Sun CL, Ness KK, Berano The J, Wu J, Francisco L, et al. Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study. JAMA Oncol. 2016;2:1277–86.

    Article  Google Scholar 

  9. Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, et al. Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: results from a prospective longitudinal study. J Clin Oncol. 2018;36:463–75.

    Article  CAS  Google Scholar 

  10. Pandya C, Magnuson A, Flannery M, Zittel J, Duberstein P, Loh KP, et al. Association between symptom burden and physical function in older patients with cancer. J Am Geriatr Soc. 2019;67:998–1004.

    Article  Google Scholar 

  11. Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, et al. Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst. 2019;111:1245–54.

    CAS  PubMed  Google Scholar 

  12. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–7.

    Article  CAS  Google Scholar 

  13. El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, et al. Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1341–8.

    Article  Google Scholar 

  14. Hamilton BK, Storer BE, Wood WA, Pidala JA, Cutler CS, Martin PJ, et al. Disability related to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26:772–7.

    Article  Google Scholar 

  15. Hamada R, Kondo T, Murao M, Miyasaka J, Yoshida M, Nankaku M, et al. Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2020;28:3189–96.

    Article  Google Scholar 

  16. Demark-Wahnefried W, Clipp EC, Morey MC, Piper CF, Sloane R, Snyder DC, et al. Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. J Clin Oncol. 2006;24:3465–73.

    Article  Google Scholar 

Download references

Acknowledgements

This research was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748 and the Program Project Grant P01 CA023766. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Editorial assistance was provided by Hannah Rice, Editor in the life sciences (ELS). RJL acknowledges research support from New York State Empire Clinical Research Investigator Program (ECRIP). AAT is supported by a grant from the Alfonso Martin Escudero Foundation. This work is partially presented at the 2020 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, Orlando, FL, USA.

Author information

Authors and Affiliations

Authors

Contributions

RJL, BKG, AS, AAJ, and SAG designed the research. RJL, REB, and SAG analyzed the data. RJL, TAE, MAM, GLS, MS, IP, CC, AAT, NCF, MSE, and LYSS collected and managed essential data. JWY, RT, BCS, CSS, DMP, BG, MAP, EBP, PBD, AAJ, JNB, and SAG provided patients and collected data. RJL wrote the paper and all authors edited and approved the paper.

Corresponding author

Correspondence to Richard J. Lin.

Ethics declarations

Conflict of interest

SAGAdvisory Board for Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz Pharmaceuticals, Takeda, Novartis, Kite, Spectrum Pharma; Research funding from Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi, Takeda. CSSConsultant on advisory boards for: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Precision Biosciences. Kite—a Gilead Company and GSK: GlaxoSmithKline. Research funds for investigator-initiated trials from: Juno Therapeutics and Sanofi-Genzyme. GLS—Research funding from Janssen and Amgen. MS—Consultancy and research funding: Angiocrine Bioscience; Consultancy: McKinsey & Company; Consultancy on Advisory Boards for: Omeros Corporation and Kite—A Gilead Company. JNB—Research funding: Angiocrine Bioscience and Merck. PBDAdvisory board of Kite (Gilead). IP—Research funding: Merck; DSMB member: ExCellThera. MAPHonoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. Research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec. The remaining authors declare no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, R.J., Baser, R.E., Elko, T.A. et al. Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56, 289–292 (2021). https://doi.org/10.1038/s41409-020-01001-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-01001-2

This article is cited by

Search

Quick links